AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension

The medicine was well tolerated, with no unexpected safety issue

FDA expands medtronic MiniMed 780G system

Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Brenntag Specialties selected European distributor for Kerry’s pharmaceutical-grade acetates

Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates

Merck’s oral PCSK9 inhibitor Enlicitide shows promising results in phase 3 CORALreef lipids study

Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol

Merck appoints David Weinreich as new Global Head of R&D and CMO for Healthcare Business

He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career

FDA approves Sanofi’s BTK inhibitor for immune thrombocytopenia

ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life

Glenmark Pharmaceuticals USA to launch Eribulin Mesylate injection

Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai

Revvity establishes In Vivo Imaging Center of Excellence in North Carolina

Facility designed to advance the next generation of imaging systems

Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity

Replicate will receive research funding and could potentially receive up to approximately US$550 million